ProfileGDS5678 / 1424080_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 67% 67% 70% 70% 63% 62% 67% 69% 69% 67% 67% 66% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7892563
GSM967853U87-EV human glioblastoma xenograft - Control 24.0560467
GSM967854U87-EV human glioblastoma xenograft - Control 34.0776467
GSM967855U87-EV human glioblastoma xenograft - Control 44.4220370
GSM967856U87-EV human glioblastoma xenograft - Control 54.3980770
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8210563
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7639562
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0612367
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2231369
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2299269
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0621367
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0809367
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9773166
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2057869